Tumor enhancement on dynamic CT

A predictive factor for recurrence after nephrectomy in localized T1 clear cell renal cell carcinoma

Junki Maehara, Akihiro Nishie, Yoshiki Asayama, Kosei Ishigami, yasuhiro ushijima, Yukihisa Takayama, Daisuke Okamoto, nobuhiro fujita, Masaaki Sugimoto, Junichi Inokuchi, Hiroshi Honda

Research output: Contribution to journalArticle

Abstract

Aim: To investigate whether radiological parameters obtained on dynamic computed tomography (CT), especially those related to tumor enhancement, are predictive factors for recurrence after nephrectomy in localized stage T1 clear cell renal cell carcinoma (ccRCC). Materials and Methods: We retrospectively studied 88 patients with localized stage T1 ccRCC who underwent dynamic CT preoperatively. Seven patients had recurrent disease after surgery. Tumor attenuations were measured by placing a region of interest in the solid region. TApre and TAneph were defined as the tumor attenuation values of the pre-contrast and nephrographic phase, respectively. The correlations between disease-free survival and clinicopathological factors, including the radiological parameter TAneph – TApre (ΔTAneph), were analyzed by Cox proportional hazards model or Kaplan–Meier method with the log-rank test. Results: Only ΔTAneph was significantly and positively correlated with disease-free survival (p<0.05). Tumor size also tended to be negatively correlated with disease-free survival (p<0.1). The 5- and 10-year disease-free survival rates of the group with high ΔTAneph (≥86 HU) were 97.4% and 97.4%, while those of the group with low ΔTAneph (<86 HU) were 89.6% and 71.6%, respectively. Conclusion: Tumor enhancement in the nephrographic phase of CT was a predictive factor for recurrence after nephrectomy in patients with localized stage T1 ccRCC.

Original languageEnglish
Pages (from-to)2377-2383
Number of pages7
JournalAnticancer research
Volume38
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Nephrectomy
Renal Cell Carcinoma
Tomography
Disease-Free Survival
Recurrence
Neoplasms
Proportional Hazards Models
Survival Rate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Tumor enhancement on dynamic CT : A predictive factor for recurrence after nephrectomy in localized T1 clear cell renal cell carcinoma. / Maehara, Junki; Nishie, Akihiro; Asayama, Yoshiki; Ishigami, Kosei; ushijima, yasuhiro; Takayama, Yukihisa; Okamoto, Daisuke; fujita, nobuhiro; Sugimoto, Masaaki; Inokuchi, Junichi; Honda, Hiroshi.

In: Anticancer research, Vol. 38, No. 4, 01.04.2018, p. 2377-2383.

Research output: Contribution to journalArticle

@article{d91c14d6adb04d7bb2ab137198cf731a,
title = "Tumor enhancement on dynamic CT: A predictive factor for recurrence after nephrectomy in localized T1 clear cell renal cell carcinoma",
abstract = "Aim: To investigate whether radiological parameters obtained on dynamic computed tomography (CT), especially those related to tumor enhancement, are predictive factors for recurrence after nephrectomy in localized stage T1 clear cell renal cell carcinoma (ccRCC). Materials and Methods: We retrospectively studied 88 patients with localized stage T1 ccRCC who underwent dynamic CT preoperatively. Seven patients had recurrent disease after surgery. Tumor attenuations were measured by placing a region of interest in the solid region. TApre and TAneph were defined as the tumor attenuation values of the pre-contrast and nephrographic phase, respectively. The correlations between disease-free survival and clinicopathological factors, including the radiological parameter TAneph – TApre (ΔTAneph), were analyzed by Cox proportional hazards model or Kaplan–Meier method with the log-rank test. Results: Only ΔTAneph was significantly and positively correlated with disease-free survival (p<0.05). Tumor size also tended to be negatively correlated with disease-free survival (p<0.1). The 5- and 10-year disease-free survival rates of the group with high ΔTAneph (≥86 HU) were 97.4{\%} and 97.4{\%}, while those of the group with low ΔTAneph (<86 HU) were 89.6{\%} and 71.6{\%}, respectively. Conclusion: Tumor enhancement in the nephrographic phase of CT was a predictive factor for recurrence after nephrectomy in patients with localized stage T1 ccRCC.",
author = "Junki Maehara and Akihiro Nishie and Yoshiki Asayama and Kosei Ishigami and yasuhiro ushijima and Yukihisa Takayama and Daisuke Okamoto and nobuhiro fujita and Masaaki Sugimoto and Junichi Inokuchi and Hiroshi Honda",
year = "2018",
month = "4",
day = "1",
doi = "10.21873/anticanres.12486",
language = "English",
volume = "38",
pages = "2377--2383",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Tumor enhancement on dynamic CT

T2 - A predictive factor for recurrence after nephrectomy in localized T1 clear cell renal cell carcinoma

AU - Maehara, Junki

AU - Nishie, Akihiro

AU - Asayama, Yoshiki

AU - Ishigami, Kosei

AU - ushijima, yasuhiro

AU - Takayama, Yukihisa

AU - Okamoto, Daisuke

AU - fujita, nobuhiro

AU - Sugimoto, Masaaki

AU - Inokuchi, Junichi

AU - Honda, Hiroshi

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Aim: To investigate whether radiological parameters obtained on dynamic computed tomography (CT), especially those related to tumor enhancement, are predictive factors for recurrence after nephrectomy in localized stage T1 clear cell renal cell carcinoma (ccRCC). Materials and Methods: We retrospectively studied 88 patients with localized stage T1 ccRCC who underwent dynamic CT preoperatively. Seven patients had recurrent disease after surgery. Tumor attenuations were measured by placing a region of interest in the solid region. TApre and TAneph were defined as the tumor attenuation values of the pre-contrast and nephrographic phase, respectively. The correlations between disease-free survival and clinicopathological factors, including the radiological parameter TAneph – TApre (ΔTAneph), were analyzed by Cox proportional hazards model or Kaplan–Meier method with the log-rank test. Results: Only ΔTAneph was significantly and positively correlated with disease-free survival (p<0.05). Tumor size also tended to be negatively correlated with disease-free survival (p<0.1). The 5- and 10-year disease-free survival rates of the group with high ΔTAneph (≥86 HU) were 97.4% and 97.4%, while those of the group with low ΔTAneph (<86 HU) were 89.6% and 71.6%, respectively. Conclusion: Tumor enhancement in the nephrographic phase of CT was a predictive factor for recurrence after nephrectomy in patients with localized stage T1 ccRCC.

AB - Aim: To investigate whether radiological parameters obtained on dynamic computed tomography (CT), especially those related to tumor enhancement, are predictive factors for recurrence after nephrectomy in localized stage T1 clear cell renal cell carcinoma (ccRCC). Materials and Methods: We retrospectively studied 88 patients with localized stage T1 ccRCC who underwent dynamic CT preoperatively. Seven patients had recurrent disease after surgery. Tumor attenuations were measured by placing a region of interest in the solid region. TApre and TAneph were defined as the tumor attenuation values of the pre-contrast and nephrographic phase, respectively. The correlations between disease-free survival and clinicopathological factors, including the radiological parameter TAneph – TApre (ΔTAneph), were analyzed by Cox proportional hazards model or Kaplan–Meier method with the log-rank test. Results: Only ΔTAneph was significantly and positively correlated with disease-free survival (p<0.05). Tumor size also tended to be negatively correlated with disease-free survival (p<0.1). The 5- and 10-year disease-free survival rates of the group with high ΔTAneph (≥86 HU) were 97.4% and 97.4%, while those of the group with low ΔTAneph (<86 HU) were 89.6% and 71.6%, respectively. Conclusion: Tumor enhancement in the nephrographic phase of CT was a predictive factor for recurrence after nephrectomy in patients with localized stage T1 ccRCC.

UR - http://www.scopus.com/inward/record.url?scp=85045090094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045090094&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12486

DO - 10.21873/anticanres.12486

M3 - Article

VL - 38

SP - 2377

EP - 2383

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -